Evidence map›Paper›PMID 32950644›Full record

ArticleNeurobiology of disease2020

Divergent FUS phosphorylation in primate and mouse cells following double-strand DNA damage.

Michelle A Johnson, Qiudong Deng, Georgia Taylor, Zachary T McEachin, Anthony W S Chan, Jessica Root, Gary J Bassell, Thomas Kukar

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michelle A JohnsonDepartment of Pharmacology and Chemical Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Center for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America.
Qiudong DengDepartment of Pharmacology and Chemical Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Center for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America.
Georgia TaylorDepartment of Pharmacology and Chemical Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Center for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America.
Zachary T McEachinCenter for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America; Department of Cell Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Laboratory of Translational Cell Biology, Emory University, School of Medicine, Atlanta, GA, United States of America.
Anthony W S ChanCenter for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America; Department of Human Genetics, Emory University, School of Medicine, Atlanta, GA, United States of America; Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, 954 Gatewood Rd, NE, Atlanta, GA, United States of America.
Jessica RootDepartment of Pharmacology and Chemical Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Center for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America.
Gary J BassellCenter for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America; Department of Cell Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Laboratory of Translational Cell Biology, Emory University, School of Medicine, Atlanta, GA, United States of America.
Thomas KukarDepartment of Pharmacology and Chemical Biology, Emory University, School of Medicine, Atlanta, GA, United States of America; Center for Neurodegenerative Disease, Emory University, School of Medicine, Atlanta, GA, United States of America; Department of Neurology, Emory University, School of Medicine, Atlanta, GA, United States of America. Electronic address: Thomas.Kukar@emory.edu.
Emory University · US

Funding

The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI WINGO, THOMAS SPURGEON · 2005 to 2019
$25.7M
Training In Systems And Integrative Biology NeuroscienceT32NS096050 · NINDS · EMORY UNIVERSITY · PI Yoland Smith · 2016 to 2026
$3.9M
Molecular mechanisms of Progranulin in NeurodegenerationR01NS105971 · NINDS · EMORY UNIVERSITY · PI KUKAR, THOMAS L · 2018 to 2022
$1.9M
Defining the role of FUS phosphorylation in neurodegenerationR01NS093362 · NINDS · EMORY UNIVERSITY · PI KUKAR, THOMAS L · 2015 to 2019
$1.7M
Selective modulation of Gamma-secretase processing through substrate bindingR00AG032362 · NIA · EMORY UNIVERSITY · PI KUKAR, THOMAS L · 2012 to 2014
$713k
Selective modulation of y-secretase processing through substrate bindingK99AG032362 · NIA · MAYO CLINIC JACKSONVILLE · PI KUKAR, THOMAS L · 2009 to 2010
$180k
NIA NIH HHS K99 AG032362NIA NIH HHS P50 AG025688NIA NIH HHS R00 AG032362NINDS NIH HHS R01 NS093362NINDS NIH HHS R01 NS105971NINDS NIH HHS T32 NS096050
6 · The paper itself

Abstract

Fused in sarcoma (FUS) is a RNA/DNA protein involved in multiple nuclear and cytoplasmic functions including transcription, splicing, mRNA trafficking, and stress granule formation. To accomplish these many functions, FUS must shuttle between cellular compartments in a highly regulated manner. When shuttling is disrupted, FUS abnormally accumulates into cytoplasmic inclusions that can be toxic. Disrupted shuttling of FUS into the nucleus is a hallmark of ~10% of frontotemporal lobar degeneration (FTLD) cases, the neuropathology that underlies frontotemporal dementia (FTD). Multiple pathways are known to disrupt nuclear/cytoplasmic shuttling of FUS. In earlier work, we discovered that double-strand DNA breaks (DSBs) trigger DNA-dependent protein kinase (DNA-PK) to phosphorylate FUS (p-FUS) at N-terminal residues leading to the cytoplasmic accumulation of FUS. Therefore, DNA damage may contribute to the development of FTLD pathology with FUS inclusions. In the present study, we examined how DSBs effect FUS phosphorylation in various primate and mouse cellular models. All cell lines derived from human and non-human primates exhibit N-terminal FUS phosphorylation following calicheamicin γ1 (CLM) induced DSBs. In contrast, we were unable to detect FUS phosphorylation in mouse-derived primary neurons or immortalized cell lines regardless of CLM treatment, duration, or concentration. Despite DNA damage induced by CLM treatment, we find that mouse cells do not phosphorylate FUS, likely due to reduced levels and activity of DNA-PK compared to human cells. Taken together, our work reveals that mouse-derived cellular models regulate FUS in an anomalous manner compared to primate cells. This raises the possibility that mouse models may not fully recapitulate the pathogenic cascades that lead to FTLD with FUS pathology.

Indexed as

AnimalsBrainDNADNA DamageFrontotemporal Lobar DegenerationHumansInclusion BodiesMiceMutationNeuronsPhosphorylationRNA-Binding Protein FUSTATA-Binding Protein Associated FactorsDNARNA-Binding Protein FUSTATA-Binding Protein Associated FactorsAmyotrophic lateral sclerosis (ALS)Calicheamicin γ1 (CLM)DNA damageDNA-dependent protein kinase (DNA-PK)Frontotemporal dementia (FTD)Fused in sarcoma (FUS)PhosphorylationSpecies specific response

Identifiers

PMID32950644
PMCPMC8064403
OpenAlexW3087253197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.